SEC Filings - Lyell Immunopharma, Inc.

Filing date	Form	Description	View
May 28, 2021	CORRESP	CORRESP	0001193125-21-177261.pdf 0001193125-21-177261.rtf 0001193125-21-177261.xls View HTML
May 01, 2024	CORRESP	CORRESP	0001193125-24-127548.pdf 0001193125-24-127548.rtf 0001193125-24-127548.xls View HTML
Apr 28, 2022	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001140361-22-016525.pdf 0001140361-22-016525.rtf 0001140361-22-016525.xls View HTML
Apr 27, 2023	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001140361-23-020919.pdf 0001140361-23-020919.rtf 0001140361-23-020919.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Apr 22, 2024	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001140361-24-021008.pdf 0001140361-24-021008.rtf 0001140361-24-021008.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Apr 27, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001140361-23-020926.pdf 0001140361-23-020926.rtf 0001140361-23-020926.xls View HTML
Apr 22, 2024	DEFA14A	Additional proxy soliciting materials - definitive	0001140361-24-021011.pdf 0001140361-24-021011.rtf 0001140361-24-021011.xls View HTML
Apr 12, 2021	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0000950123-21-004496.pdf 0000950123-21-004496.rtf 0000950123-21-004496.xls View HTML
May 12, 2021	DRS/A	Amendment to a previously filed DRS	0000950123-21-006098.pdf 0000950123-21-006098.rtf 0000950123-21-006098.xls View HTML
Jun 16, 2021	EFFECT	EFFECT	9999999995-21-002371.pdf 9999999995-21-002371.rtf 9999999995-21-002371.xls View HTML

Data provided by Kaleidoscope.

RSS Feeds

Email Alerts